

25 September 2020

ASX Market Announcement Office
20 Bridge Street
SYDNEY NSW 2000

Amended Appendix 3Y for Yeshween Mudaliar


The Company wishes to advise that an amended Appendix 3Y attached has been lodged.

The following information has changed as a result of the Termination of the Long-Term Incentive Plan (Plan) as announced by the company earlier today:

- The date of change has been corrected to 25 September 2020;
- The number of performance rights disposed as a result of the cancellation of the Plan is 2,500,000; and
- Hence the interest held by the Managing Director after effecting these changes is Nil.

Should you have any queries or require further information please do not hesitate to contact us.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Indira Naidu', enclosed within a hand-drawn oval.

Indira Naidu
Company Secretary

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity MEDILAND PHARM LIMITED
ABN 83 628 420 824

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Yeshween Mudaliar
Date of last notice	28 February 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	25 September 2020
No. of securities held prior to change	2,500,000 Performance Rights
Class	Unlisted Options
Number acquired	-
Number disposed	2,500,000 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights Granted under LTIP FY2019 have been cancelled. Long Term Incentive Plan FY 19 has been terminated effective 25 September 2020
---	---

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.